Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

InMed Pharmaceuticals Inc. INM

Healthcare  —  Drug Manufacturers Specialty & Generic
1.38 (0.02) (1.43%) as of 25 Sep
Market cap
$7.7M
P/E
0.0×
Revenue Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

InMed Pharmaceuticals Inc. (INM) Business Profile

Updated before January 2025

Company Overview

InMed Pharmaceuticals Inc. (INM) is a leading biopharmaceutical company specializing in the research, development, and commercialization of rare cannabinoids and cannabinoid-based pharmaceutical products. Founded in 2014 and headquartered in Vancouver, Canada, the company has established itself as a pioneer in the cannabinoid space, leveraging its proprietary biosynthesis technology and pharmaceutical expertise to address unmet medical needs.

The company is led by a team of seasoned professionals with extensive experience in biotechnology, pharmaceuticals, and cannabinoid research. Eric A. Adams serves as the President and Chief Executive Officer, bringing over 25 years of leadership in the life sciences industry. Other key members of the leadership team include Dr. Eric Hsu, Senior Vice President of Preclinical Research and Development, and Alexandra Djuric, Vice President of Clinical and Regulatory Affairs. Together, they drive InMed’s mission to improve patient outcomes through innovative cannabinoid-based therapies.

Core Business Segments

Pharmaceutical Cannabinoids

InMed Pharmaceuticals focuses on developing cannabinoid-based therapies for rare and serious diseases. The company’s pipeline includes:

  • INM-755: A topical cream designed for the treatment of Epidermolysis Bullosa (EB), a rare genetic skin disorder. INM-755 is currently in clinical trials and has shown promising results in reducing inflammation and improving skin integrity.
  • INM-088: A cannabinoid-based eye drop formulation targeting glaucoma. This product aims to reduce intraocular pressure and protect retinal cells, addressing a significant unmet need in ophthalmology.

Rare Cannabinoid Manufacturing

InMed is a leader in the biosynthesis of rare cannabinoids, utilizing its proprietary IntegraSyn™ technology. This platform enables the cost-effective and scalable production of cannabinoids such as cannabidivarin (CBDV) and tetrahydrocannabivarin (THCV), which are difficult to extract in large quantities from cannabis plants. These rare cannabinoids have potential therapeutic applications in areas such as pain management, neurological disorders, and metabolic diseases.

Contract Manufacturing and Licensing

In addition to its proprietary products, InMed offers contract manufacturing services to other companies in the cannabinoid industry. The company licenses its IntegraSyn™ technology to partners, generating additional revenue streams while expanding the adoption of its innovative biosynthesis platform.

Business Model

InMed Pharmaceuticals operates on a hybrid business model that integrates product development, manufacturing, and licensing. The company generates revenue through multiple channels:

  1. Product Sales: Revenue from the commercialization of cannabinoid-based pharmaceutical products.
  2. Licensing Agreements: Income from licensing its IntegraSyn™ biosynthesis technology to third-party manufacturers and research organizations.
  3. Contract Manufacturing: Fees for producing rare cannabinoids for other companies using its proprietary technology.

This diversified approach allows InMed to mitigate risks associated with product development while capitalizing on the growing demand for cannabinoids in both pharmaceutical and consumer markets.

Strategic Direction

InMed Pharmaceuticals is focused on achieving long-term growth through innovation and strategic partnerships. Key elements of its strategic direction include:

  • Advancing Clinical Programs: The company aims to bring its lead candidates, INM-755 and INM-088, to market by completing clinical trials and obtaining regulatory approvals.
  • Expanding Biosynthesis Capabilities: InMed plans to enhance its IntegraSyn™ platform to produce a broader range of rare cannabinoids, addressing diverse therapeutic needs.
  • Sustainability Goals: By utilizing biosynthesis technology, InMed reduces the environmental impact associated with traditional cannabis cultivation and extraction methods.
  • Exploring New Applications: The company is actively researching additional therapeutic areas where rare cannabinoids can provide significant benefits, such as neurodegenerative diseases and chronic pain.

Competitive Landscape

InMed Pharmaceuticals operates in a highly competitive market, facing competition from both pharmaceutical companies and cannabinoid-focused startups. Key competitors include:

  • GW Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals): A leader in cannabinoid-based medicines, known for its FDA-approved products like Epidiolex.
  • Zynerba Pharmaceuticals: Specializes in transdermal cannabinoid therapies.
  • Cronos Group: Focuses on cannabinoid production and research, leveraging biosynthesis technology.
  • Amyris Inc.: A biotechnology company with expertise in synthetic biology and cannabinoid production.

Despite the competition, InMed differentiates itself through its focus on rare cannabinoids and its proprietary biosynthesis platform, which offers cost and scalability advantages.

Risk Factors

Like any biopharmaceutical company, InMed faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The development and approval of cannabinoid-based therapies are subject to stringent regulatory requirements, which can delay product launches.
  • Market Dependence: The company’s success is heavily reliant on the commercialization of its lead candidates, INM-755 and INM-088.
  • Supply Chain Disruptions: Dependence on specialized raw materials and manufacturing processes makes the company vulnerable to supply chain issues.
  • Competitive Pressure: The rapidly evolving cannabinoid market poses a risk of obsolescence if competitors develop superior products or technologies.

Recent Developments

InMed Pharmaceuticals has made significant strides in recent months:

  • Clinical Trial Progress: The company announced positive interim results from its Phase 2 clinical trial of INM-755 for Epidermolysis Bullosa, demonstrating safety and efficacy.
  • IntegraSyn™ Milestone: InMed achieved a breakthrough in its biosynthesis platform, increasing the yield and efficiency of rare cannabinoid production.
  • Strategic Partnerships: The company entered into licensing agreements with global partners to expand the adoption of its biosynthesis technology.
  • COVID-19 Impact: While the pandemic posed challenges, InMed successfully adapted its operations, ensuring continuity in research and development activities.

Investment Considerations

Strengths

  • Innovative Technology: Proprietary IntegraSyn™ platform offers a competitive edge in cannabinoid production.
  • Diverse Revenue Streams: Multiple income sources reduce dependency on a single product.
  • Experienced Leadership: A seasoned management team with a proven track record in biotechnology.

Risks

  • Regulatory Uncertainty: Delays in clinical trials or approvals could impact timelines.
  • Market Competition: Intense competition from established players and new entrants.
  • Financial Constraints: As a pre-commercial company, InMed relies on external funding to support its operations.

Conclusion

InMed Pharmaceuticals Inc. is well-positioned to capitalize on the growing demand for cannabinoid-based therapies. With its innovative biosynthesis technology, robust product pipeline, and strategic focus on rare cannabinoids, the company has the potential to become a leader in the biopharmaceutical industry. While challenges remain, InMed’s commitment to innovation and patient-centric solutions provides a strong foundation for future growth.